Denali Therapeutics Q3 2026: What's Behind the EPS Beat
As seen on the 24/7 Wall St. homepage on November 3, 2026.
The swing to positive EPS came from a one-time $194 million gain on a Priority Review Voucher sale, with an operating loss of $126.8 million. On the Hunter syndrome launch, revenue missed expectations, but management guided fourth-quarter AVLAYAH sales to $30 million to $32 million as payer coverage widened past 70% of US commercial lives.
Continue ReadingShow less
Denali Therapeutics swung to a reported GAAP profit of $0.37 per share in the third quarter of 2026, beating expectations for a loss of $0.37 per share. A one-time $194 million gain from the sale of a Priority Review Voucher did the heavy lifting. Excluding it, the company carried an operating loss consistent with where Denali has been for years as it funds a broad pipeline of blood-brain barrier therapies.
AVLAYAH, the company's Hunter syndrome therapy and its only commercial product, generated $17.8 million in net product sales during the quarter, missing expectations. That gap will draw scrutiny, particularly because AVLAYAH is still in only its second full commercial quarter and the market had priced in a steeper ramp.
The commercial setup heading into the fourth quarter looks meaningfully better than the third-quarter miss might suggest. Payer coverage expanded to more than 70% of U.S. commercial lives, and 20 state Medicaid programs have published coverage policies. A permanent J-code that took effect October 1 also removes a billing friction point that had complicated uptake at treatment centers. Management guided Q4 AVLAYAH revenue to $30 million to $32 million, implying roughly double the Q3 run rate.
Sponsored
Beyond the AVLAYAH launch, CEO Ryan Watts pointed to zafinofusp alfa for Sanfilippo syndrome type A as the next commercial product, with a BLA submission seeking accelerated approval planned for 2027. Additional Phase 1/2 data are expected at a medical congress in the first quarter of 2027, and a global Phase 3 confirmatory study is already in start-up. Five TransportVehicle platform programs spanning Alzheimer's disease, FTD GRN, and Pompe disease are also expected to generate data in 2027, making the next twelve months a dense period for pipeline catalysts.
Investors watching the balance sheet will note that total liabilities rose 155% year over year to $329.6 million, in large part due to a new liability under a revenue participation right agreement. The company acknowledged in its risk disclosures that it needs to consider additional capital, a standard but relevant caveat for a business still running deep operating losses outside of one-time items.
Mentioned: DNLI